Can Ketamine For Depression Be Improved? New Study Will Look Into Ketamine Analog Arketamine
Perception Neuroscience, an Atai Life Sciences (NASDAQ: ATAI) subsidiary, is starting a Phase 2a clinical trial on PCN-101, its lead drug candidate.
Can MDMA Treat Traumatic Brain Injury? $1.5 Million Are Being Committed To Finding Out
Wesana Health (CSE: WESA) (OTCQB: WSNAF) and the Multidisciplinary Association for Psychedelic Studies (MAPS) are teaming up to analyze the effectiveness of MDMA-assisted therapy in the treatment of traumatic brain injury (TBI).
If California Governor Newsom Is Voted Out Of Office Today, The Cannabis Industry Could Suffer
On Tuesday, California voters will decide whether Governor Gavin Newsom will continue his first term or be removed from office through a recall vote.
Meet The Top 12 CEOs In The Psychedelics Industry
By Natan Ponieman and Javier Hasse
The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other serious conditions.
Field Trip Stock Could Climb 300% In One Year
On Wednesday, HC WainWright began coverage of Field Trip Health (NASDAQ: FTRP), a company in the psychedelics space, which is developi
Sugarmade Snags Licenses For 3 New Cannabis Delivery Hubs In L.A.
California cannabis marketplace company Sugarmade, Inc. (OTCPINK: SGMD) has signed a definitive agreement to obtain three non-storefront cannabis licenses in the Los Angeles area.
Khiron’s First Two CBD Products Now Available At Pharmacies In Peru
Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) announced on Tuesday that it has registered its first two finished medical cannabis products in Peru.
$925M Acquisition Of Redecan Could Create A Brighter Future For Hexo Corp.
Cantor Fitzgerald issued a new report on Hexo Corp. (TSX: HEXO) (NASDAQ: HEXO) after the company announced the $925 million acquisition of Rede